Medicsight ColonCAD Technology Successfully Identified Cancer in 100% of Patients Included in Data Presented at ...( NEW YORK June 18 /- Medicsight PL...),Health

NEW YORK, June 18 /PRNewswire-FirstCall/ -- Medicsight PLC (AIM: MDST), a subsidiary of MGT Capital Investments, Inc. (Amex: MGT) (the "Company"), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announced that data presented at the recent European Society of Gastrointestinal and Abdominal Radiology (ESGAR) in Istanbul showed that the use of the Medicsight Computer-Aided Detection (CAD) helped radiographers to detect 100% of cancers when examining more than 300 patients in routine primary reporting of virtual colonoscopy (VC).

"These findings are exciting because whilst demand for colorectal cancer investigation is on the rise, there is a shortage of radiologists trained to report VC in many countries," said Dr David Burling, Consultant Radiologist from St Mark's Hospital, London. "If radiographers can be trained to interpret scans more effectively using CAD technology, both radiology teams and patients will benefit, with the ultimate goal of decreasing the incidence and morbidity of colorectal cancer, the second most common cause of death from cancer in Europe."

In the study, 304 patients (61% female) underwent VC as part of routine clinical care. Examinations were read by two trained radiographers supplemented by CAD as a 'second reader'. Radiographers recorded colonic abnormalities and interpretation times and proposed one of six different codes for each examination (Categories S0-5: inadequate/normal/6-9 mm polyp/10mm+ polyp/cancer/diverticular stricture). Findings were compared to that of an experienced radiologist and supplemented by colonoscopic findings if available.

The radiographers, assisted by CAD detected 100% (17/17) of cancers; 72% (21/29) of
'/>"/>